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Kawasaki disease (KD) is the most common systemic vas-
culitis syndrome, primarily affecting small- to medium-
sized arteries, more particularly the coronary arteries
(Kato et al. 1996). KD was ﬁrst described in 1967 and is
now identiﬁed as the leading cause of acquired heart dis-
ease among children in developed countries (Wang et al.
2005). The annual incidence of KD in children of Japa-
nese descent is about 218 per 100,000 children less than
5 years of age (Nakamura et al. 2012) as compared to
about 20 per 100,000 in the United States (Holman et al.
2010a). Timely treatment with high-dose intravenous c
globulin (IVIG) reduces the duration of fever and inci-
dence of coronary artery lesions (CAL). However, even
after IVIG treatment ~5–7% of patients develop aneu-
rysms (Ogata et al. 2013).
It is widely believed that KD is induced by one or more
infectious agents that evoke an abnormal immunological
response in genetically susceptible individuals (Burgner
and Harnden 2005). However, since the initial description
of KD, identiﬁcation of a deﬁnitive infectious agent has
been elusive. Several lines of evidence support the infec-
tion hypothesis including the acute onset of a self-limited
illness, increased susceptibility at younger age, and geo-
graphic clustering of outbreaks with a seasonal predomi-
nance (later winter and early spring) (Wang et al. 2005).
There is a higher incidence of KD in Japan as well as
among Japanese descendants residing in the United States
than in any other ethnic populations (Holman et al.
2010b), suggesting that a genetic predisposition also plays
an important role in susceptibility to the disease. In addi-
tion, there is evidence that the incidence of KD in parents
and siblings of an affected patient is higher than in the
general population (Onouchi 2012). For example, it has
been reported that siblings of affected children are at 10-
to 30-fold greater risk of developing KD than children in
the general population (Fujita et al. 1989). In addition,
offspring of individuals diagnosed with KD are more
likely to develop KD (Uehara et al. 2004). More recently
there have been a large number of genetic linkage and
genome-wide association studies (GWAS) that have
reported genetic loci associated with risk and outcomes,
see Onouchi (2012) for a comprehensive review. Among
the loci that have been implicated in large GWAS studies
and have been replicated by separate studies are FCGR2A
(Khor et al. 2011; Onouchi et al. 2012), CASP3 (Onouchi
et al. 2010; Kuo et al. 2013), and BLK (Onouchi et al.
2012; Chang et al. 2013).
HLA-B haplotypes have also been linked to KD with
one study identifying KD-associated polymorphisms in
ABHD16A (abhydrolase domain containing 16A; also
known as BAT5: HLA-B associated transcript 5) (Hsieh
et al. 2010), this association has not been replicated by
other studies. ABHD16A encodes a highly conserved,
widely expressed lipase of unknown speciﬁcity although it
has been proposed to function as a palmitoylthioesterase
(Martin et al. 2012). ABHD16A binds to IFITM1 (inter-
feron-induced transmembrane protein 1) (Lehner et al.
2004). Another member of the family, IFITM3 (OMIM:
605579), is transcriptionally induced by type I and II in-
terferons and serves to block cellular infection by viruses
(such as inﬂuenza and dengue) that require endosomal
entry into the cytoplasm for replication (Brass et al. 2009;
Jiang et al. 2010; Weidner et al. 2010; Lu et al. 2011).
An allelic variant in the human IFITM3 gene (SNP
rs12252: NM_021034.2:c.42T>C; p.Ser14=) truncates the
ﬁrst 20 amino acids of the protein by introducing an
alternative splice site and results in the loss of its “anti-
viral” function (Everitt et al. 2012). Everitt and colleagues
also showed that for European Caucasian patients infected
with inﬂuenza A H1N1/09 virus, those homozygous for
the C allele were signiﬁcantly more likely to develop
severe infections requiring hospitalization. More recently,
Zhang et al. (2013) made a similar observation in Chinese
patients infected with H1N1/09 inﬂuenza. The objectives
of the study were (1) to evaluate for differences in
IFITM3 genotype frequencies between KD and control
cohorts, (2) to assess whether there are differences in the
incidences of CAL among the three KD genotypes, and
(3) to assess for differences in the distributions of demo-
graphic factors (age, gender), IVIG treatment, laboratory
data (C-reactive protein [CRP] levels and numbers of
white blood cells [WBC]), and duration of fever.
In this study, we genotyped 140 KD patients recruited
at three centers, the University of Toyama (n = 89),
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sity of Utah (n = 41), for the rs12252 SNP. Patients were
diagnosed with KD according to standard diagnostic cri-
teria (Kawasaki et al. 1974; Kawasaki 1979). All patients
were treated with IVIG and oral aspirin at the time of
diagnosis. Echocardiography was used to determine
whether the patients had developed CAL, deﬁned as a
coronary artery with a diameter of 3 mm or more (4 mm
if the subject was over the age of 5 year) at ≥1 month
after the onset of KD (Shulman et al. 1995).
With informed consent, venous blood samples or buccal
swabs were obtained at the time of diagnosis and DNA iso-
lated and stored at  20°C. For genotyping, both coding ex-
ons of IFITM3 were ampliﬁed from 10 ng of genomic DNA
using Platinum Taq polymerase (Life Technologies, Carls-
bad, CA) (Arrington et al. 2012) and the oligonucleotide
primers, IFITM3_1_F: 50-CAAATGCCAGGAAAAGGA
AA-30 and IFITM3_2_R: 50-CGAGGAATGGAAGTTGGA
GT-30. The 1158 bp PCR product was analyzed by agarose
gel electrophoresis, puriﬁed by treating with Exo-SAP-IT
(Affymetrix, Santa Clara, CA), and then submitted to the
University of Utah DNA sequencing core for analysis (Ar-
rington et al. 2012). The study was approved by the Ethics
Committees of the University of Toyama and the Kanazawa
Medical University, and the Institutional Review Board of
the University of Utah.
Corresponding to the three objectives stated above, we
carried out the analyses and summarized the results in
three tables. In the ﬁrst analysis (Table 1), we reported
the distribution of KD allele and genotype frequency for
the control and the KD (case) cohort. The percentage was
the conditional probability of having the speciﬁc allele or
genotype category. These conditional probabilities were
compared between the control and case cohort, stratiﬁed
by race (white, Japanese), by using the chi-square test, or
the Fisher’s Exact test when the frequency count was less
than 5 in at least one cell in the contingency table. In the
second analysis (Table 2), the association between
CAL incidence and genotype was assessed using either
chi-square test or Fisher’s exact test. We performed four
different contingency table analyses for the overall KD
cohort (genotype, allele, dominant, recessive) and thus
have used an adjusted type-I error by the Bonferroni
method (by dividing the level of signiﬁcance 0.05 by 4
which yield 0.0125). Thus, the P-value was considered sig-
niﬁcant if it was less than 0.0125 instead of 0.05. Simi-
larly, we performed this analysis for the stratiﬁed cohort
of Asian, and white patients. In the third analysis
(Table 3), we ﬁrst assessed the shape of the distribution
of the continuous variable of age, CRP, WBC, and fever
duration and learned using the normality test of Shapiro–
Wilk and examined the histograms that these variables
did not follow near normal distribution. Thus, we also
reported the median in addition to the mean and stan-
dard deviation, overall, and for each of the three genotype
categories. We used the nonparametric Wilcoxon rank-
sum test to compare among the three groups of genotype.
For gender, and treatment response to IVIG, we used
either chi-square or Fisher’s exact test. For this table,
since all the comparisons were preplanned, and no pair-
wise comparisons were done, we maintained the type-I
error at 0.05. All of our analyses were carried out using
the SAS/STAT software version 9.3 (Cary, NC) (proce-
dure FREQ for chi-square or Fisher’s exact test, and pro-
cedure NPAR1WAY for the nonparametric Wilcoxon
rank-sum test). Allelic and genotype frequencies were
assessed for Hardy–Weinberg equilibrium using the
online calculator at http://www.oege.org/software/hwe-mr-
calc.shtml (Rodriguez et al. 2009).
All 99 patients recruited in Toyama and Kanazawa were
of Japanese descent. Of the 41 patients recruited in Utah,
37 were Caucasian (ﬁve with Hispanic ethnicity), 1 Asian,
1 Paciﬁc Islander, and 2 Alaskan Native/Native American.
Comparing the allelic frequencies and genotype distribu-
tion for rs12252 in the KD Caucasian/non-Hispanic and
Japanese patients with 1000 genome (1000g) data from
170 Caucasian/non-Hispanic and 178 Japanese patients
who did not have KD (control), did not reveal a
Table 1. Allele and genotype frequencies of the SNP rs12252 (NM_021034.2:c.42T>C) in Utah Caucasian/non-Hispanic and Japanese patients
with KD, compared with 1000 genome data for Utah and Japanese controls.
Genotype
Controls
(1000g CEU:
n = 170)
Utah White-non
Hispanic cases
(n = 32) P-value
Controls
(1000g JPT:
n = 178)
Japanese
cases (n = 99) P-value
Allele C 16 (5%) 5 (8%) 0.352 210 (63%) 121 (65%) 0.625
Allele T 324 (95%) 59 (92%) 146 (37%) 77 (35%)
CC 0 (0%) 0 (0%) 0.358 68 (38%) 38 (38%) 0.683
CT 16 (9%) 5 (16%) 74 (42%) 45 (46%)
TT 154 (91%) 27 (84%) 36 (20%) 16 (16%)
P values were obtained by chi-square test or Fisher’s exact test.
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were in Hardy–Weinberg equilibrium. Three patients from
Utah were homozygous CC, the Asian and Paciﬁc Islander
patients as well as one of the Caucasian/Hispanic patients.
Further analysis of the allelic frequencies and genotype
distribution for rs12252 identiﬁed a signiﬁcant association
with outcome. Patients who developed CAL were signiﬁ-
cantly more likely to carry the C allele (P = 0.0004) and
the distribution of genotypes was signiﬁcantly different
(P = 0.004) (Table 2). In addition, signiﬁcantly more
patients homozygous for the SNP developed CAL than
patients with the other genotypes (51.2% vs. 23.2%:
P = 0.001), supporting a recessive model for the effect of
this SNP (Table 2). There was not a signiﬁcant associa-
tion with a dominant model (P = 0.039). These associa-
tions were also true when comparing outcomes in Asian
patients (Table 2). There was not a signiﬁcant association
for Caucasians, possibly because the minor allele is very
Table 2. The C allele and CC genotype for rs12252 (NM_021034.2:c.42T>C) are signiﬁcantly associated with the development of CAL in KD
patients.
Contingency table P value
All patients
Genotype CC CT TT
CAL 21 (51%) 13 (26%) 10 (20%) 0.004
No CAL 20 (49%) 37 (74%) 39 (80%)
Allelic frequency C T
CAL 55 (42%) 33 (22%) 0.0004
No CAL 76 (58%) 116 (78%)
Genetic model
Dominant CC + CT TT
CAL 34 (37%) 10 (20%) 0.039
No CAL 57 (63%) 39 (80%)
Recessive CC CT + TT
CAL 21 (51%) 23 (23%) 0.001
No CAL 20 (49%) 76 (77%)
Asian patients
Genotype CC CT TT
CAL 20 (51%) 12 (27%) 3 (19%) 0.025
No CAL 19 (49%) 33 (77%) 13 (81%)
Allelic frequency C T
CAL 52 (42%) 18 (23%) 0.006
No CAL 71 (58%) 59 (77%)
Genetic model
Dominant CC + CT TT
CAL 32 (38%) 3 (19%) 0.164
No CAL 52 (62%) 13 (81%)
Recessive CC CT + TT
CAL 20 (51%) 15 (25%) 0.009
No CAL 19 (49%) 46 (75%)
Caucasian patients
Genotype CC CT TT
CAL 0 (0%) 1 (20%) 7 (23%) 1.000
No CAL 1 (100%) 4 (80%) 24 (77%)
Allelic frequency C T
CAL 1 (14%) 15 (22%) 1.000
No CAL 6 (86%) 52 (78%)
Genetic model
Dominant CC + CT TT
CAL 1 (17%) 7 (23%) 1.000
No CAL 5 (83%) 24 (77%)
Recessive CC CT + TT
CAL 0 (0%) 8 (22%) 1.000
No CAL 1 (100%) 28 (78%)
P values were obtained by chi-square analysis.
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son in this small cohort. There were no signiﬁcant differ-
ences in other clinical and laboratory data between
genotypes (Table 3), including the duration of fever and
the response to IVIG.
The IFITM proteins restrict the cellular entry of various
viruses, including inﬂuenza A, ﬂaviviruses, dengue virus,
West Nile virus, and severe acute respiratory syndrome
coronavirus (Brass et al. 2009; Huang et al. 2011). These
viruses share common characteristics in that they are
enveloped and enter cells via membrane fusion in endoso-
mal compartments. It has been shown that IFITM3 pre-
vents emergence of viral genomes from the endosomal
pathway, although this may be restricted to late endo-
somes or lysosomes (Feeley et al. 2011). Since many
enveloped viruses enter host cells through the late endo-
cytic pathway, it is possible that enveloped viruses are an
important etiologic agent in KD, particularly in patients
that develop CAL. The symptoms of KD suggest that tis-
sue damage may also occur from an over-reaction of the
immune response characterized by the elevated expression
of inﬂammatory cytokines (Saji and Kemmotsu 2006).
The IFITM proteins of man and mouse have also been
shown to be associated with membrane signaling com-
plexes (Smith et al. 2006), consequently the loss of func-
tional IFITM3 in KD patients may predispose to
enhanced inﬂammatory responses and tissue damage.
Among the Japanese cohort, 19 (50%) of 38 patients
carrying the CC genotype developed CAL. In the Utah
cohort, 2 (66.7%) of 3 patients homozygous for rs12252-
C developed CAL. At least in the Asian population, where
the frequency of the C allele is high, screening for this
SNP may be a relatively cost effective way to identify
patients at higher risk of developing CAL.
In conclusion, our data reveal a novel association
between the IFITM3 rs12252 CC genotype and the
development of CAL in patients with KD, particularly in
Asian patients. This association did not extend to the
susceptibility to develop KD but it is noteworthy that the
frequency of this allele is much higher in the Asian
Table 3. Comparison of clinical and laboratory data in KD patients with different rs12252 (NM_021034.2:c.42T>C) genotypes.
Demographic All KD (N = 140) CC (N = 41) CT (N = 50) TT (N = 49) P value
All patients
Age at Dx (years) 2.73   2.38 (2.37) 2.63   2.58 (1.80) 2.76   2.16 (2.00) 2.78   2.45 (2.50) 0.718
1
Gender (M/F) 94/46 29/12 29/21 36/13 0.221
2
Second dose of IVIG required 31/139
3 9/40 11/50
3 11/49 0.968
2
Laboratory data
4
CRP (mg/dL) 10.23   7.61 (8.40) 8.71   7.11 (6.37) 9.99   5.82 (8.55) 11.67   9.24 (8.85) 0.289
1
WBC/lL 15,103   4974 (14,510) 15,347   5466 (15,570) 14,174   4559 (13,400) 15,752   4922 (14,555) 0.303
1
Duration of fever (days) 9.35   4.90 (8.00) 10.47   5.72 (8.50) 9.60   4.42 (9.00) 8.27   4.52 (6.00) 0.055
1
Asian patients All KD (N = 100) CC (N = 39) CT (N = 45) TT (N = 16) P value
Age at Dx (years) 2.62   2.10 (1.90) 2.42   2.07 (1.80) 2.74   2.16 (2.00) 2.72   2.09 (2.70) 0.607
1
Gender (M/F) 64/36 27/12 26/19 11/5 0.503
2
Second dose of IVIG required 23/99 8/38 11/45
3 4/16 0.956
2
Laboratory data
CRP (mg/dL) 9.21   6.39 (7.80) 8.28   6.63 (6.37) 9.71   5.84 (8.50) 9.92   7.21 (6.75) 0.303
1
WBC/lL 14,427   4847 (13,900) 15,047   5459 (15,000) 14,116   4848 (13,500) 13,869   3521 (13,130) 0.566
1
Duration of fever (days) 10.02   5.22 (9.00) 10.81   5.72 (9.00) 9.69   4.40 (9.00) 9.20   6.05 (6.00) 0.323
1
Caucasian patients All KD (N = 37) CC (N = 1) CT (N = 5) TT (N = 31) P value
Age at Dx (years) 2.75   2.63 (2.00) 1.1   NA (1.1) 2.9   2.44 (2.00) 2.78   2.72 (2.40) 0.853
1
Gender (M/F) 27/10 1/0 3/2 23/8 0.711
2
Second dose of IVIG required 7/37 1/0 0/5 6/31 0.455
2
Laboratory data
CRP (mg/dL) 12.56   9.74 (12.20) 5.10   NA (5.10) 11.86   5.92 (13.50) 13.03   10.56 (12.20) 0.747
1
WBC/lL 16,443   5010 (15,250) 17,800   NA (17,800) 14,560   2152 (13,300) 16,779   5466 (15,250) 0.530
1
Duration of fever (days) 7.76   3.66 (6.00) 5.00   NA (5.00) 9.00   5.05 (6.00) 7.64   3.47 (6.00) 0.43
1
Mean   SD and median values (in parentheses) are reported. Dx, diagnosis; SD, standard deviation; M, male; F, female; IVIG, intravenous c globu-
lin; CRP, C-reactive protein; WBC, white blood cells; lL, microliter; NA, not applicable (one patient).
1P values obtained by nonparametric Wilcoxon rank-sum test.
2P values obtained by chi-square test and Fisher’s exact test when cell counts <5.
3Data for one patient incomplete.
4Laboratory data incomplete for 31 of the 140 patients; 9 CC, 12 CT, and 10 TT.
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leads to production of a truncated protein with reduced
ability to block viral release from the endocytic pathway,
these data suggest enveloped viruses may be an important
etiologic agent for KD and/or the development of CAL.
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